inhibitors

Newly diagnosed patients with type 2 diabetes mellitus (T2DM) should be offered a sodium–glucose co-transporter-2 (SGLT-2) inhibitor – which include dapagliflozin and empagliflozin – earlier in their treatment alongside metformin, …

The IndependentNew diabetes drug could revolutionize care for thousandsA new class of once-daily tablets, SGLT-2 inhibitors, has been found to significantly reduce premature deaths in type 2 diabetes patients..2 hours …

Initiating treatment with a sodium–glucose cotransporter-2 (SGLT2) inhibitor rather than a glucagon-like peptide-1 receptor agonist (GLP-1RA) is associated with better renal outcomes in people with type 2 diabetes, according to …

The Cureus Journal of Medical ScienceAngiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-AnalysisType 2 diabetes mellitus (T2DM) …

CureusEffects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors on Lipid Profiles in Type 2 Diabetes: A Systematic ReviewSodium glucose cotransporter 2 (SGLT2) inhibitors provide cardiometabolic benefits in adults with type …

CureusComparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisSodium-glucose cotransporter-2 (SGLT2) inhibitors …

Credit: Pixabay/CC0 Public Domain A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors have a slightly lower risk of …

The Cureus Journal of Medical ScienceSodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsSodium-glucose cotransporter-2 (SGLT2) …

The Cureus Journal of Medical ScienceCardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic ReviewType 2 …

A large cohort study found three popular GLP-1-based diabetes drugs — semaglutide, dulaglutide, and tirzepatide — carry similar risks for serious adverse GI events, with a rate of about 12 …